Russia to Ship Covid-19 Drug to Hospitals in Race for Treatment
(Bloomberg) --
Russia is preparing to provide hospitals with a coronavirus drug developed with the sovereign wealth fund's backing after gaining initial approval from the Health Ministry amid a global race to find safe and effective treatments for Covid-19.
The medicine will be shipped to hospitals starting June 11 and exports may follow once domestic demand is met, according to the Russian Direct Investment Fund, which is producing the antiviral in a joint venture with the ChemRar Group.
The treatment, Avifavir, is based on a generic version of Fujifilm Holdings Corp.'s drug Avigan, which Japan's government is still looking to approve for treatment of coronavirus. Final-stage clinical trials of Russia's Avifavir involving 330 patients are continuing, according to the wealth fund.
As the coronavirus continues to spread, upending economies and life around the world, drug companies have been racing to develop treatments and vaccines. Clinical trials showed Avifavir helped reduce the number of days a person is infected and cut the period of high fever, according to the RDIF.
Russia now joins the U.S, China and Japan, which have drugs registered for use against coronavirus in hospitals, according to RDIF. Avifavir is the second drug, after Remdesivir, to show promising results against Covid-19 and ChemRar Group will deliver 60,000 doses this month, RDIF CEO Kirill Dmitriev said on a conference call Monday.
On Saturday, Dmitriev called Avifavir “perhaps the most promising anti-Covid-19 drug in the world.” He praised the “unprecedentedly short period of time” in which Russia has prepared the medicine.
Where Are We in Quest for Coronavirus Drugs, Vaccine?: QuickTake
Companies around the world are considering producing versions of Avigan, or favipiravir, which in a non-randomized Chinese study in March resulted in faster clearance of the virus in comparison with an anti-HIV drug. Yohei Doi, the lead researcher on an Avigan trial, said last month that it's too early to make a call on whether the drug works or not against Covid-19, and patients are still being enrolled.
Russia has recorded the world's third-highest number of Covid-19 infection cases, according to Johns Hopkins University's research center. Russian cases exceeded 414,878 on Monday, while the reported death toll remains relatively low among some of the world's largest countries, at 4,855.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.